Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Berzosertib - Merck KGaA

Drug Profile

Berzosertib - Merck KGaA

Alternative Names: Captisol® enabled VX 970; M6620; VX-970

Latest Information Update: 26 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vertex Pharmaceuticals
  • Developer EMD Serono Research & Development Institute; Massachusetts General Hospital; Merck KGaA; National Cancer Institute (USA); University of Oxford
  • Class Amines; Antineoplastics; Isoxazoles; Pyrazines; Radiation-sensitising agents; Small molecules
  • Mechanism of Action ATR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Small cell lung cancer; Solid tumours; Urogenital cancer
  • Phase I Breast cancer; Non-small cell lung cancer; Oesophageal cancer
  • Preclinical Acute myeloid leukaemia

Most Recent Events

  • 14 Nov 2019 Phase-II clinical trials in Small cell lung cancer (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT04162041)
  • 06 Nov 2019 EMD Serono and Merck complete a phase II trial in Ovarian cancer, Fallopian tube cancer and Peritoneal cancer in the UK, USA and Belgium (IV) (NCT03704467)
  • 14 Aug 2019 National Cancer Institute plans a phase I trial for Breast cancer in November 2019 (NCT04052555)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top